Aardvark Therapeutics, Inc. expected to post a loss of 87 cents a share - Earnings Preview

Aardvark Therapeutics

07/08/2026 14:55

Aardvark Therapeutics, Inc. AARD.OQ AARD.O is expected to  show no change in quarterly revenue when it reports  results on August 11 (estimated) for the period ending June 30 2026

​LSEG's mean analyst estimate for Aardvark Therapeutics, Inc. is for a loss of 87 cents per share. 
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy," 4 "hold" and 2 "sell" or "strong sell."  
The mean earnings estimate of analysts was unchanged in the last three months. ​
Wall Street's median 12-month price target for Aardvark Therapeutics, Inc. is $7.00, about 4.1% below its last closing price of $7.30
Previous quarterly performance (using preferred earnings measure in US dollars). ​
QUARTER ENDING
STARMINESMARTESTIMATE®
LSEG IBES ESTIMATE 
ACTUAL
BEAT, MET, MISSED
SURPRISE %
Mar. 31 2026
-0.86
-0.88
-0.99
Missed
-12.8
Dec. 31 2026
-0.82
-0.83
-0.81
Beat
2.7
Sep. 30 2025
-0.84
-0.80
-0.75
Beat
6.1​
Jun. 30 2025
-0.59
-0.60
-0.66
Missed
-10
​​Mar. 31 2025
-0.67
-0.67
-0.71
Missed
-5.4
​
This summary was machine generated August 7 at 13:55 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)